Agenus shared a post on LinkedIn:
“Agenus will present a poster at the AACR Immuno-Oncology Conference (AACR-IO) 2026, highlighting biomarker analyses from the investigational BOT+BAL immunotherapy program.
Los Angeles
Poster presentation: Thursday, February 19
Time: 12:15-3:15PM PT / 3:15-6:15 PM ET
The accepted abstract focuses on systemic and tumor-microenvironment inflammation in patients with immunologically “cold,” treatment-refractory cancers treated with botensilimab alone or in combination with balstilimab.
Read the full press release.”
More posts about Agenus.